bioRxiv Science⌕ Search

Biology subjects

Jansen, J. H.

Publications and source records attributed to Jansen, J. H..

3 recordsLinked to original sources

Methylome profiling of SetDB1 deficient ESCs reveals diverse epigenetic cross-talk during pluripotency

SetDB1 is best known as a chromatin modifier catalyzing H3K9me3. However, recent studies show that SetDB1 can promote H3K27me3-deposition and CTCF-binding, and potentially recruit de novo DNA methyltransferases. Given the tight connection with these processes, we hypothesized that DNA methylation (DNAme) may integrate these combined features of SetDB1. Thereto, we conducted time-course whole-genome bisulfite sequencing following Setdb1 knockout (KO) in mouse embryonic stem cells (ESCs). In serum-cultured ESCs, nearly half of SetDB1 binding sites are DNA methylated, coinciding with H3K9me3, mainly silencing retrotransposons and imprinting control regions. Both H3K9me3 and DNAme are lost upon Setdb1 KO, but while TET2 rapidly removes DNAme at many of these sites, some retrotransposons are shielded from TET2 and lose DNAme slowly via passive dilution. SetDB1-mediated regulation via H3K27me3, CTCF, SMAD3, and histone acetylation are uncoupled from the DNAme-H3K9me3 axis. Hypomethylated naive ESCs show massive reactivation of retrotransposons upon Setdb1 KO, providing functional evidence that DNAme adds a protective layer against such activity. Altogether, our findings reveal how DNAme coordinates the multifaceted regulatory roles of SetDB1. HighlightsO_LIIn serum ESCs, SetDB1-dependent deposition of H3K9me3 and DNAme are tightly coupled, primarily silencing repeats and imprinted control regions; C_LIO_LILoss of SetDB1 causes demethylation of a large range of repeat types, the pace of which is dependent on TET pre-loading; C_LIO_LIThe regulatory modes of SetDB1 mediated by H3K27me3, CTCF, TGF-{beta} signalling and histone acetylation are uncoupled from the SetDB1 DNAme-H3K9me3 axis and/or from each other; C_LIO_LILoss of SetDB1-dependent DNAme in hypomethylated 2i ESCs reveals that DNAme serves as a buffering layer to repress SetDB1-mediated H3K9me3 targets. C_LI

molecular biology↗

The exit of naïve pluripotency contains a lipid metabolism-induced checkpoint for genome integrity.

Pluripotent progenitors undergo dramatic cellular and biochemical transformations during peri-implantation development. These large-scale reprogramming events are fundamental for subsequent differentiation, but how they are integrated and co-ordinated with the preservation of genome integrity remain unknown. Here, we uncover a metabolism-induced telomere checkpoint that takes place in pluripotent progenitors as they form rosette-like epithelial structures. We show that the glycolytic switch at the exit of naive pluripotency is preceded by an acceleration of mitochondrial respiration and de novo lipogenesis, fuelling the accumulation of lipid droplets required for morphogenesis. We find that downstream of these CIDEA-promoted metabolic events is the induction of ZSCAN4, a key pluripotency-associated regulator of telomere stability. Surprisingly, the build-up of lipid droplets corresponds to a transient shortening of telomeres, which triggers the activation of an elongation mechanism via ZSCAN4. Thus, telomere homeostasis can be safeguarded as essential lipid metabolic reprogramming unfolds to drive developmental progression.

developmental biology↗

The neuronal homeobox transcription factor HMX3 is a crucial vulnerability factor in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia

The KMT2A::MLLT3 fusion protein causes acute myeloid leukemia (AML) by activating the oncogenic transcription factor MECOM. However, MECOM expression occurs in only half of the KMT2A::MLLT3 cases. By integrating gene expression and enhancer activity data from patient cells, we identified neuronal homeobox transcription factor HMX3 as cell fate determining factor in MECOM-negative KMT2A::MLLT3 AML. HMX3 expression associated with younger age and KMT2A-rearranged leukemia in large AML cohorts (p<0.002). HMX3 was not expressed in other major genetic risk groups and healthy blood cells. Transcriptomic analyses revealed that HMX3 drives cancer-associated E2F, MYC and cell cycle gene programs. Ectopic HMX3 expression completely inhibited monocytic but not granulocytic colony formation of healthy CD34+ adult cells. Silencing of HMX3 in KMT2A::MLLT3 AML cell lines and patient cells resulted in cell cycle arrest, monocytic differentiation, and apoptosis. Thus, HMX3 is a leukemia-specific vulnerability that enhances proliferation and blocks differentiation of MECOM-negative KMT2A::MLLT3 leukemia.

cancer biology↗